Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer

Abstract

To clarify the association between carboplatin and electrolyte abnormality, a pooled-analysis was performed with the adverse event reports of non-small cell lung cancer patients. A total of 19901 adverse events were retrieved from the FDA Adverse Event Reporting System (FAERS). Pooled reporting odds ratios (RORs) and 95% CIs suggested that carboplatin was significantly associated with hyponatremia (pooled ROR = 1.57, 95% CI 1.18-2.09, P = 1.99×10-3) and hypokalemia (pooled ROR = 2.37, 95% CI 1.80-3.10, P = 5.24×10-10) as compared to other therapies. In addition, we found that dehydration was frequently concurrent with carboplatin therapy (pooled ROR = 2.01, 95% CI 1.52-2.66, P = 8.37×10-7), which may prompt excessive water ingestion and decrease serum electrolyte concentrations. This information has not been mentioned in the FDA-approved drug label and could help explain the physiological mechanism of carboplatin-induced electrolyte abnormality. In conclusion, the above results will facilitate clinical management and prompt intervention of life-threatening electrolyte imbalance in the course of cancer treatment.

DOI: 10.18632/oncotarget.12813

4 Figures and Tables

Cite this paper

@inproceedings{Ma2017IncidenceAP, title={Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer}, author={Yushui Ma and Likun Hou and Fei Yu and Gaixia Lu and Shanshan Qin and Ruting Xie and Huiqiong Yang and Tingmiao Wu and Pei Luo and Li Kheng Chai and Zhongwei Lv and Xiaodong Peng and Chunyan Wu and Da Fu}, booktitle={Oncotarget}, year={2017} }